We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Hemolytic Anemia Secondary to Stibophen Therapy

Mercedes V. Vda. de Torregrosa, PhD; Angel L. Rodriguez Rosado, MD; Eduardo Montilla, MD
JAMA. 1963;186(6):598-599. doi:10.1001/jama.1963.63710060044021b.
Text Size: A A A
Published online


STIBOPHEN (Fuadin) (sodium antimony III biscatechol-2-4 disulfonate heptahydrate), is an anthelmintic which since 1929 has been used extensively in the treatment of schistosomiasis. The manufacturers claim that toxicity is low and that severe side effects have not been observed. Transient nausea, vomiting, headache, diarrhea, and muscular and joint pains have been the most frequently observed side effects. Thrombocytopenia has been the most common hematological complication.1

In 1956 Harris2,3 described the occurrence of hemolytic anemia in a patient who was receiving stibophen therapy. Furthermore, he found that when stibophen was added to the patient's serum, antibodies active against cells from the patient and compatible red blood cells could be demonstrated. The patient had a positive direct and indirect Coombs' test.

In 1960, a similar case occurred but the antibodies appeared to be of the saline agglutinating type. During 1961, two cases of stibophen-induced hemolytic anemia came to our attention.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.